Contents
Issue 147 • October 2024
In association with
In Depth
Prodrugs and patents: enhancing therapy adherence and reducing side effects
Are PBMs to blame for high drug prices in the US?
Into the unknown: how quickly can vaccines be developed for Disease X
US negotiations for first round of drugs reveal $6bn in Medicare savings
Emerging microbiome market – unlocking new frontiers
Build or buy? Key considerations for in-house manufacturing